ENCEFA is a biotechnology company developing novel CD38 modulators that clean up suffering cells (whole autophagy-lysosomal flux activation) and boost their energy metabolism, making them effective again in the context of age-related diseases. 
ENCEFA leverages on the discovery of a new biological pathway that uses CD38 in an unprecedent manner (3 patents filed), by simply mimicking a key natural rescue mechanism every one of us physiologically have, but which is impaired with aging, while beside increasing NAD+ levels.
Stemming from the Pitié Salpêtrière Hospital, Paris, FRANCE, and incorporated in 2016, ENCEFA is on a mission to extend our Healthy Longevity. 
 
Through this novel anti-aging mechanism, our products shown their ability to rejuvenate the key organs of our body and to calm down inflammation, under several pathological contexts in a preclinical setting (mice, rats, dogs).

Our most advanced product, NC-B8, is a first-in-class brain penetrant antibody, developed against neurodegenerative diseases, starting with Amyotrophic Lateral Sclerosis (ALS). 

NC-P7, is our second product activating the same anti-aging mechanism of action, developed to protect the heart and the kidney in the context of age-related metabolic disorders.

ENCEFA

Org chart

Teams

Offices